|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
MYOCARDIAL DEPRESSION MAY BE POTENTIATED
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|